Akero Therapeutics, Inc.
AKRO
$38.29
-$1.70-4.25%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
2/28/2025
-
MarketBeat
4/4/2025
-
MarketBeat
4/3/2025
-
Tickeron - Stocks
4/2/2025
-
24/7 Wall St.
4/2/2025
-
Tickeron - Stocks
4/1/2025
-
Tickeron - Stocks
4/1/2025
-
Tickeron - Stocks
4/1/2025
-
MarketBeat
3/31/2025
-
Simply Wall St
3/29/2025
-
MarketBeat
3/29/2025
-
MarketBeat
3/29/2025
-
MarketBeat
3/28/2025
-
Insider Monkey
3/28/2025
-
Market News Video
3/28/2025
-
Ticker Report
3/28/2025
-
Ticker Report
3/27/2025
-
MarketBeat
3/27/2025
-
Tickeron - Stocks
3/26/2025
-
Ticker Report
3/26/2025
-
MarketBeat
3/24/2025
-
MarketBeat
3/21/2025
-
Tickeron - Stocks
3/21/2025
-
Ticker Report
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, February 28, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 487 6488
Address
601 Gateway Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an...
more
